Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats

Life Sciences

Volumn 83, Issue 7-8, 2008, Pages 229-235

  Abe, Fumie ^a   Ueyama, Jun ^b   Kimata, Akiko ^b   Kato, Miki ^a   Hayashi, Tamon ^a   Nadai, Masayuki ^c   Saito, Hiroko ^a   Takeyama, Naoshi ^a   Noguchi, Hiroshi ^a   Hasegawa, Takaaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c MEIJO UNIVERSITY   (Japan)

Author keywords

Eisai hyperbilirubinemic rats (EHBR); Hepatobiliary excretion; Micafungin; Multidrug resistance associated protein 2 (ABCC2 Mrp2)

Indexed keywords

CYCLOSPORIN; MICAFUNGIN; MULTIDRUG RESISTANCE PROTEIN 2;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; DRUG TRANSPORT; EISAI HYPERBILIRUBINEMIC RAT; GENETIC DISORDER; LIVER CLEARANCE; MALE; NONHUMAN; PROTEIN FUNCTION; RAT; RAT STRAIN; SPRAGUE DAWLEY RAT; STEADY STATE;

ANIMALS; ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BIOLOGICAL TRANSPORT; CYCLOSPORINE; ECHINOCANDINS; ENZYME INHIBITORS; HYPERBILIRUBINEMIA; INJECTIONS, INTRAVENOUS; LIPOPROTEINS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 48549092508     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.06.013     Document Type: Article

References (28)

1. Akita H., Suzuki H., and Sugiyama Y. Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharmaceutical Research 18 8 (2001) 1119-1125
2. Asakura E., Nakayama H., Sugie M., Zhao Y.L., Nadai M., Kitaichi K., Shimizu A., Miyoshi M., Takagi K., Takagi K., and Hasegawa T. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. European Journal of Pharmacology 484 2-3 (2004) 333-339
3. Borst P., Evers R., Kool M., and Wijnholds J. The multidrug resistance protein family. Biochimica et Biophysica Acta 1461 2 (1999) 347-357
4. Chen Z.S., Kawabe T., Ono M., Aoki S., Sumizawa T., Furukawa T., Uchiumi T., Wada M., Kuwano M., and Akiyama S. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Molecular Pharmacology 56 6 (1999) 1219-1228
5. Gotoh Y., Suzuki H., Kinoshita S., Hirohashi T., Kato Y., and Sugiyama Y. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. Journal of Pharmacology and Experimental Therapeutics 292 1 (2000) 433-439
6. Hebert M.F., Blough D.K., Townsend R.W., Allison M., Buell D., Keirns J., and Bekersky I. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology 45 9 (2005) 1018-1024
7. Hebert M.F., Townsend R.W., Austin S., Balan G., Blough D.K., Buell D., Keirns J., and Bekersky I. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology 45 8 (2005) 954-960
8. Hidemura K., Zhao Y.L., Ito K., Nakao A., Kanazawa H., Takagi K., Ohta M., and Hasegawa T. Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P-glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrobial Agents and Chemotherapy 47 5 (2003) 1636-1642
9. Hirohashi T., Suzuki H., Ito K., Ogawa K., Kume K., Shimizu T., and Sugiyama Y. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Molecular Pharmacology 53 6 (1998) 1068-1075
10. Kaneko H., Yamato Y., Teramura Y., Fujiwara T., Suzuki A., Kawarura A., Terakawa M., and Kagayama A. Metabolites of micafungin in rats and dogs. Japanese Journal of Chemotherapy 50 Suppl. 1 (2002) 88-93
11. Kiso S., Cai S.H., Kitaichi K., Furui N., Takagi K., Takagi K., Nabeshima T., and Hasegawa T. Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Anticancer Research 20 5A (2000) 2827-2834
12. Konishi H., Sudo M., Sumi M., Morii H., Minouchi T., Aimoto T., and Yamaji A. Pharmacokinetic behavior of micafungin in rats with carbon tetrachloride-induced acute hepatic failure. Biological and Pharmaceutical Bulletin 28 3 (2005) 556-559
13. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijin J.A., Baas F., and Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Research 57 16 (1997) 3537-3547
14. Mayer R., Kartenbeck J., Büchler M., Jedlitschky G., Leier I., and Kuppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. Journal of Cell Biology 131 1 (1995) 137-150
15. Mizuno N., Niwa T., Yotsumoto Y., and Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacological Reviews 55 3 (2003) 425-461
16. Newton D.J., Wang R.W., and Evans D.C. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2-deficient TR- and EHBR rats. Life Sciences 77 10 (2005) 1106-1115
17. Sakaeda T., Iwaki K., Kakumoto M., Nishikawa M., Niwa T., Jin J.S., Nakamura T., Nishiguchi K., Okamura N., and Okumura K. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. Journal of Pharmacy and Pharmacology 57 6 (2005) 759-764
18. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 97 11 (1996) 2517-2524
19. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smith J.J., van der Valk M.A., Voordouw A.C., Spits H., van Tellingen O., Zijlmans J.M., Fibbe W.E., and Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences of the United States of America 94 8 (1997) 4028-4032
20. Shimizu A., Miyoshi M., Sugie M., Ueyama J., Yamaguchi T., Sasaki T., Takagi K., Jin M., Miyamoto K.-I., Tsuji A., and Hasegawa T. Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. European Journal of Pharmacology 501 1-3 (2004) 151-159
21. Shitara Y., Sugiyama D., Kusuhara H., Kato Y., Abe T., Meier P.J., Itoh T., and Sugiyama Y. Comparative inhibitory effects of different compounds on rat oatp1 (Slc21a1)- and oatp2 (Slc21a5)-mediated transport. Pharmaceutical Research 19 2 (2002) 147-153
22. Sugie M., Asakura E., Zhao Y.L., Torita S., Nadai M., Baba K., Kitaichi K., Takagi K., Takagi K., and Hasegawa T. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrobial Agents and Chemotherapy 48 3 (2004) 809-814
23. Takenaka O., Horie T., Kobayashi K., Suzuki H., and Sugiyama Y. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharmaceutical Research 12 11 (1995) 1746-1755
24. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America 84 21 (1987) 7735-7738
25. Wacher V.J., Wu C.Y., and Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis 13 3 (1995) 129-134
26. Yamaguchi S., Zhao Y.L., Nadai M., Yoshizumi H., Cen X., Torita S., Takagi K., Takagi K., and Hasegawa T. Involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrobial Agents and Chemotherapy 50 1 (2006) 80-87
27. 14C] micafungin to rats. Japanese Journal of Chemotherapy 50 Suppl. 1 (2002) 80-87
28. Yamazaki M., Suzuki H., and Sugiyama Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharmaceutical Research 13 4 (1996) 497-513